because many people believed that obesity wasn’t a chronic disease, but rather the result of poor lifestyle choices, medication wasn’t available. that said, “the understanding of obesity and how that works in our body and the consequences have evolved over time,” leading to a collection of different medications, such as glp-1 receptor agonists, dual gip and glp-1 receptor agonists, and fat-digestion blockers.
it’s not just medications that are changing regarding treatment. it’s also the understanding of individuals and how medications can and should be used for those who have obesity, which can cause other health consequences.
dr. rowe notes that the old guidelines looked at body mass index, more commonly known as bmi, as the main factor to determine whether a person would be approved to access obesity medications. but the disease is so complex, as is each case.
“the recommendation is to make sure that we’re taking into consideration gender and ethnicity-specific indications for treatment because we have found that people with different ethnicities and different genders have those medical complications of obesity at different sizes,” she said.
other factors that have gone into consideration to update the guidelines focus on not body size overall, but what the risk of complications is for each person living with obesity. for example, someone who lives with obesity but in a smaller body than someone else who has the disease may be more at risk of severe complications, even though they’re in a smaller body.